Please check your internet connection and try again.
## Lorazepam
### Overview
Lorazepam is a benzodiazepine with anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant properties. It acts by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) in the central nervous system.
### Primary Indications
* Anxiety disorders
* Insomnia (short-term treatment)
* Premedication for surgical procedures
* Management of status epilepticus
* Sedation in intensive care settings
### Adult Dosing
* **Anxiety:** Usual starting dose is 1-2 mg orally 2-3 times daily. May increase to 1-4 mg orally 2-3 times daily. Maximum: 10 mg/day.
* **Insomnia:** 2-4 mg orally at bedtime.
* **Premedication:** 2-4 mg IM or IV 1-2 hours before surgery.
* **Status Epilepticus:** 4 mg IV initially. May repeat every 5-10 minutes up to a maximum of 8 mg in a 12-hour period (or per local protocol, often a second dose of 4 mg is given if seizures persist). Intramuscular (IM) administration may be an alternative if IV access is not readily available.
### Pediatric Dosing
Dosing in children is highly variable and less well-established than in adults. Doses should be individualized based on age, weight, and clinical response.
* **Premedication:** Typically 0.05 mg/kg IV (maximum 2 mg) 1-2 hours before surgery.
* **Status Epilepticus:** 0.1 mg/kg IV (maximum 4 mg). Repeat if necessary after 5-10 minutes.
* **Anxiety/Sedation:** Dosing varies widely; consult pediatric-specific guidelines or reference.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution; may require dose reduction.
* **Renal Impairment:** Use with caution; consider dose reduction, especially in severe impairment.
* **Elderly:** Increased sensitivity; generally start with lower doses (e.g., half the adult starting dose) and titrate slowly.
### Contraindications
* Known hypersensitivity to lorazepam, other benzodiazepines, or any component of the formulation.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency (though caution is advised rather than absolute contraindication in some cases).
* Sleep apnea.
### Adverse Effects
Common: Drowsiness, dizziness, sedation, fatigue, ataxia, weakness, confusion.
Less Common: Paradoxical excitation, amnesia, depression, dysarthria, hypotension.
Serious: Respiratory depression, coma, dependence, withdrawal symptoms, anterograde amnesia.
### Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other sedatives/hypnotics):** Additive CNS depression, increased risk of sedation, respiratory depression, and potentially fatal outcomes. Use together with extreme caution and consider dose reduction of one or both agents.
* **Theophyllines/Aminophylline:** May reduce the sedative effects of lorazepam.
* **Valproic acid:** May increase plasma concentrations of lorazepam; consider dose reduction of lorazepam.
### Monitoring
* Level of sedation, respiratory rate, and oxygen saturation, especially with IV administration or in combination with other CNS depressants.
* Signs of dependence and withdrawal if used long-term.
* Hepatic and renal function in patients with impaired organ function.
* Effectiveness for the intended indication.
### Clinical Pearls
* Lorazepam is a Schedule IV controlled substance.
* Intravenous lorazepam formulation contains polyethylene glycol and propylene glycol, which can cause toxicity in patients with renal or hepatic impairment, and potentially in neonates with IV administration.
* Intramuscular absorption can be slower and more variable than IV.
* Abrupt discontinuation after prolonged use can lead to withdrawal symptoms, including seizures. Tapering of the dose is recommended.
* Use for insomnia should be short-term due to risk of dependence and tolerance.
***
*Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and recommendations may vary based on individual patient factors and local institutional protocols.*
